Lu sur http://onlinelibrary.wiley.com/doi/10.1 ... avedsearch cette publication intitulée
" Syndrome myasthénique de Lambert-Eaton: épidémiologie et intervention thérapeutique dans la population nationale des anciens combattants ...(des USA*) "
*ajout de notre part pour la compréhension du titre...
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Lambert–Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population
Daniel C. Abenroth MD1,2, A. Gordon Smith MD2, John E. Greenlee MD1,2, Sharon D. Austin PhD3 andStacey L. Clardy MD, PhD1,2,*
Version of Record online: 17 MAR 2017
One nationwide study (The Netherlands) of Lambert–Eaton myasthenic syndrome (LEMS) has been published. We report LEMS epidemiology and its therapeutic response in the United States Veterans Affairs (VA) population.
Medical records for all active patients (12.5 million) in the VA health system were queried for relevant ICD-9 codes for the period October 1, 1999 to September 30, 2013. Clinical, electrophysiologic, and serologic features were evaluated to confirm diagnosis; epidemiologic and treatment data were collected.
Point prevalence was estimated at 2.8 per 1,000,000 (confirmed cases) and 3.8 per 1,000,000 (combined confirmed and probable cases). Crude incidence was similarly estimated at 0.6 and 0.7 per 1,000,000 per year, respectively. A total of 18 of 48 (38%) patients received 3,4-diaminopyridine (3,4-DAP); 14 of 18 (78%) improved.
This investigation was a large North American epidemiologic study of LEMS. LEMS prevalence and incidence in the national VA population was found to be similar to previously published rates in other large international populations. Most patients experienced improvement with therapy, including a majority with 3,4-DAP.
Muscle Nerve, 2016